viral
infect
remain
import
caus
morbid
mortal
hematopoiet
cell
transplant
recipi
recent
develop
prepar
regimen
graft
manipul
well
control
wellrecogn
posttranspl
infect
introduct
prophylaxi
preemptiv
strategi
influenc
time
epidemiolog
infect
new
pathogen
human
metapneumoviru
hmpv
human
bocaviru
human
coronavirus
human
herpesvirus
polyomavirus
emerg
fundament
determin
signific
newli
discov
virus
role
transplant
field
articl
summar
recent
data
epidemiolog
laboratori
diagnosi
new
pathogen
well
clinic
featur
manag
associ
infecti
complic
transplant
hematopoiet
stem
cell
deriv
three
sourc
bone
marrow
thoma
et
al
b
peripher
blood
schmitz
et
al
umbil
cord
blood
gluckman
et
al
either
autolog
haurani
allogen
et
al
establish
year
treatment
choic
varieti
hematolog
malign
nonmalign
diseas
hematopoiet
cell
transplant
defin
intraven
infus
progenitor
hematopoiet
cell
capabl
establish
longterm
stabl
myeloid
hematolog
immunolog
function
thoma
blume
diseas
entiti
hematopoiet
cell
transplant
correct
inherit
acquir
defici
normal
product
hematopoiet
cell
immun
function
case
rescu
hemopoiesi
highdos
chemoradiotherapi
malign
promot
power
graft
versu
leukemia
effect
adopt
immunotherapi
et
al
kolb
et
al
aggress
induct
regimen
util
hematopoiet
cell
transplant
may
result
multipl
organ
toxic
furthermor
prolong
time
engraft
use
immunosuppress
result
increas
risk
bacteri
viral
fungal
infect
frassoni
et
al
infect
main
caus
death
stem
cell
transplant
especi
allogen
transplant
support
care
major
concern
order
diminish
infecti
complic
use
growth
factor
rapid
hemopoiet
engraft
reduc
aplast
phase
consequ
neutropen
febril
episod
hugh
et
al
occurr
infecti
complic
roughli
follow
pattern
immun
reconstitut
highli
influenc
allogen
transplant
acut
chronic
graft
versu
host
diseas
gvhd
billingham
increas
use
altern
donor
led
intensifi
immunosuppress
regimen
acut
chronic
gvhd
modifi
time
fungal
viral
infect
new
approach
hematopoiet
cell
transplant
undertaken
new
infecti
complic
observ
cordonni
mauri
sinc
first
success
allogen
transplant
three
children
sever
combin
immunodefici
gatti
et
al
patient
transplant
worldwid
today
patient
undergo
type
transplant
annual
wherea
registri
european
bone
marrow
transplant
report
carri
hematopoiet
cell
transplant
allogen
autolog
addit
transplant
europ
main
indic
leukemia
case
allogen
transplant
lymphoma
autolog
transplant
gratwohl
et
al
reason
global
spread
hematopoiet
cell
transplant
first
document
potenti
efficaci
mani
diseas
entiti
second
bigger
pool
avail
donor
altern
option
transplant
ie
relat
haploident
unrel
transplant
doubl
cord
blood
transplant
last
improv
support
care
bacteri
viral
fungal
infect
lead
reduc
morbid
mortal
relat
method
new
era
need
unrel
donor
initi
patient
possibl
sibl
donor
first
allogen
transplant
unrel
hla
compat
donor
perform
hansen
et
al
kaminski
petersdorf
et
al
sinc
nation
marrow
donor
program
nmdp
fund
million
donor
avail
approxim
hematopoiet
cell
transplant
unrel
donor
carri
annual
involv
donor
differ
countri
altern
option
patient
transplant
haploident
relat
donor
ie
one
share
haplotyp
donor
probabl
make
alway
easili
avail
type
transplant
need
design
certain
condit
post
highli
intensifi
prepar
regimen
b
infus
megados
purifi
cell
avoid
reject
gvhd
simultan
major
disadvantag
haploident
transplant
late
immun
reconstitut
high
cytomegaloviru
cmv
infect
rate
effort
enhanc
immun
reconstitut
schedul
genet
engin
donor
lymphocyt
infus
herp
simplex
viru
thymidin
kinas
suicid
gene
administ
destroy
drug
ganciclovir
presenc
gvhd
bonini
et
al
anoth
valuabl
graft
sourc
recogn
cord
blood
initi
use
pediatr
patient
due
limit
number
cell
gluckman
et
al
main
advantag
cord
blood
transplant
graft
readi
use
alreadi
prescreen
infect
hla
cryopreserv
appli
even
hla
dispar
due
low
immunogen
nevertheless
disadvantag
cord
blood
graft
follow
low
stem
cell
count
prolong
neutropenia
increas
infect
lack
access
donor
lymphocyt
infus
manag
relaps
transplant
doubl
cord
blood
unit
demonstr
team
minnesota
barker
et
al
effect
promis
adult
high
bodi
weight
sinc
major
breakthrough
achiev
transplant
field
use
reduc
intens
condit
widen
candid
popul
allogen
transplant
term
older
age
also
term
diseas
well
niederwies
et
al
bacigalupo
patient
undergo
hematopoiet
cell
transplant
post
reduc
intens
condit
appear
shorter
neutropenia
period
fewer
bacteremia
episod
well
viral
infect
first
day
compar
transplant
myeloabl
regimen
baron
et
al
furthermor
number
sever
viral
infect
cmv
reactiv
cmv
diseas
lower
first
day
incid
invas
aspergillosi
similar
two
type
transplant
first
year
fukuda
et
al
cmv
infect
remain
sever
complic
patient
especi
late
posttranspl
period
cmv
infect
major
fatal
threat
transplant
patient
prevent
cmv
seroposit
patient
either
prophylact
preemptiv
antivir
treatment
ganciclovirfoscarnet
noteworthi
earli
detect
virus
great
import
best
manag
polici
remain
lower
gradual
taper
immunosuppress
kontoyianni
et
al
addit
one
major
achiev
recognit
import
risk
assess
develop
posttranspl
viral
infect
assess
made
sever
virus
pretranspl
detect
viral
statu
patient
sever
virus
donor
ljungman
number
altern
transplant
increas
profound
tcell
deplet
need
therefor
viral
infect
remain
signific
predictor
transplant
outcom
still
main
caus
morbid
mortal
year
major
improv
posttranspl
manag
viral
infect
achiev
especi
wellrecogn
pathogen
cmv
herp
simplex
viru
hsv
varicellazost
viru
vzv
respiratori
syncyti
viru
rsv
adenoviru
parainfluenza
virus
influenza
virus
develop
new
diagnost
molecular
techniqu
led
recognit
new
virus
transplant
patient
review
attempt
describ
role
emerg
virus
hmpv
human
bocaviru
human
coronavirus
human
herpesvirus
polyomavirus
hematopoiet
graft
recipi
tabl
discoveri
hmpv
new
paramyxoviru
first
identifi
children
respiratori
tract
diseas
report
van
den
hoogen
et
al
negativesens
nonseg
rna
paramyxoviru
famili
paramyxovirida
subfamili
pneumovirina
appear
least
two
major
genotyp
hmpv
b
hmpv
infect
identifi
worldwid
age
children
seroposit
reinfect
winter
epidem
occur
throughout
life
health
protect
agenc
account
approxim
communityacquir
pneumonia
adult
johnston
et
al
bronchiol
young
children
kahn
hmpv
infect
detect
hematopoiet
graft
recipi
peck
et
al
whether
asymptomat
infect
occur
remain
defin
debiaggi
et
al
peck
et
al
hmpv
detect
bronchoalveolar
lavag
sampl
hematopoiet
transplant
recipi
clinic
radiograph
sign
pneumonia
idiopath
pneumonia
syndrom
initi
diagnosi
major
patient
englund
et
al
role
hmpv
respiratori
pathogen
confirm
experiment
infect
cynomolg
macaqu
kuiken
et
al
symptomat
asymptomat
upper
lower
respiratori
tract
diseas
occur
immunocompet
young
older
adult
resid
longterm
nurs
care
facil
clinic
featur
similar
seen
adult
infect
rsv
ie
infect
upper
respiratori
tract
bronchiol
pneumonia
otiti
media
sever
diseas
activ
associ
hmpv
infect
immunocompromis
patient
kahn
hematopoiet
transplant
recipi
hmpv
diseas
report
present
upper
respiratori
symptom
includ
fever
nasal
congest
cough
pneumonia
develop
rapidli
progress
pulmonari
infiltr
accompani
frequent
hypotens
septic
shock
observ
englund
et
al
recent
kamboj
et
al
found
hmpv
infect
cancer
patient
caus
number
unspecif
respiratori
symptom
observ
fatal
case
respiratori
hmpv
infect
seri
recent
studi
bronchoalveolar
lavag
sampl
immunocompromis
patient
atyp
pneumonia
examin
hmpv
detect
male
patient
undergon
allogen
bone
marrow
transplant
due
chronic
myeloid
leukemia
unfortun
patient
succumb
sever
aggrav
atyp
pneumonia
fatal
pulmonari
failur
day
admiss
ller
et
al
laboratori
diagnosi
mainli
base
pcr
techniqu
perform
primer
mainli
target
conserv
fragment
nucleotid
lpolymeras
gene
primer
also
success
use
target
region
n
gene
debiaggi
et
al
cultur
difficult
inappropri
routin
diagnosi
commerci
antigen
detect
test
develop
detect
indirect
fluoresc
assay
use
monoclon
antibodi
also
use
test
manoha
et
al
regard
new
hmpv
detect
kit
use
immunochromatographi
sa
hmpv
test
overal
sensit
specif
respect
suggest
test
use
especi
pediatrician
diagnos
hmpv
infect
clinic
set
matsuzaki
et
al
although
establish
treatment
hmpv
diseas
hematopoiet
cell
transplant
recipi
boeckh
two
case
treat
success
combin
intraven
ribavirin
immunoglobulin
bonney
et
al
kambl
et
al
sever
candid
hmpv
vaccin
develop
one
shown
promis
result
experiment
anim
howev
studi
human
perform
yet
kahn
hmpv
monoclon
antibodi
neutral
genotyp
b
virus
develop
shown
protect
experiment
anim
hmpv
infect
ulbrandt
et
al
compound
sulfat
sialyl
lipid
potent
hmpv
antivir
activ
cell
cultur
assay
wyde
et
al
recent
studi
treatment
improv
sever
aspect
hmpvinduc
diseas
balbc
mice
infect
hmpv
consid
evalu
anim
model
spetch
et
al
human
bocaviru
hbov
discov
septemb
alland
et
al
viru
assign
new
member
famili
parvovirida
subfamili
parvovirina
genu
bocaviru
provision
term
human
bocaviru
first
human
member
viru
genu
schildgen
et
al
fact
hbov
first
detect
nasopharyng
aspir
patient
respiratori
tract
infect
pathogen
detect
suggest
viru
may
pathogen
role
respiratori
tract
diseas
alland
et
al
multipl
studi
identifi
presenc
hbov
respiratori
tract
sampl
recent
studi
identifi
hbov
also
blood
fecal
sampl
arnold
et
al
fri
et
al
qu
et
al
schenk
et
al
costa
et
al
report
suggest
hbov
worldwid
endem
primarili
found
young
children
true
incid
season
primari
hbov
infect
remain
unknown
coinfect
hbov
common
respiratori
virus
may
common
kahn
sever
clinic
research
group
report
hbovposit
immunosuppressedimmunodefici
patient
schildgen
et
al
dissemin
nasopharyng
aspir
serum
fece
hbov
infect
report
child
stem
cell
transplant
present
pneumonia
perihilar
infiltr
schenk
et
al
hbov
sole
pathogen
found
nasopharyng
aspir
sampl
adult
immunosuppress
patient
malign
bcell
lymphoma
sever
infect
longlast
fever
pneumonia
kupfer
et
al
dissemin
hbov
infect
also
report
immunodefici
child
clinic
hepat
skin
manifest
noteworthi
respiratori
find
concomit
virus
detect
kainulainen
et
al
occurr
hbov
febril
children
acut
lymphoblast
leukemia
koskenvuo
et
al
prospect
studi
hbov
preval
consecut
bronchoalveolar
lavag
sampl
italian
adult
patient
hbov
detect
hematopoiet
graft
recipi
develop
pneumonia
acut
respiratori
defici
costa
et
al
clinic
symptom
frequent
report
individu
hbov
isol
viru
includ
cough
rhinorrhea
fever
wheez
diarrhea
arnold
et
al
gastrointestin
symptom
describ
hbovinfect
patient
arnold
et
al
kesebir
et
al
monteni
et
al
sever
studi
includ
control
group
asymptomat
children
found
statist
associ
hbov
acut
respiratori
symptom
way
consist
causal
role
schildgen
et
al
howev
role
hbov
respiratori
pathogen
remain
controversi
hbov
codetect
frequenc
report
alland
et
al
fri
et
al
also
import
note
high
frequenc
hbov
detect
asymptomat
children
report
studi
longtin
et
al
furthermor
recent
studi
shown
absenc
hbov
bronchoalveolar
lavag
cohort
lung
transplant
patient
miyaki
et
al
detect
hbov
perform
convent
realtim
pcr
choi
et
al
sinc
anim
model
infect
antibodi
prepar
antigen
detect
avail
limit
genet
variabl
hbov
multipl
suitabl
pcr
target
use
includ
moreconserv
genet
region
gene
frequent
target
gene
schildgen
et
al
cultur
hbov
possibl
first
cultur
differenti
human
airway
epitheli
cell
dijkman
et
al
hbov
dna
initi
found
respiratori
secret
also
detect
stool
serum
suggest
viru
caus
system
infect
kahn
applic
serolog
pcr
detect
blood
expect
use
diagnost
tool
hbov
infect
seem
frequent
follow
asymptomat
low
level
viru
shed
respiratori
tract
alland
antivir
drug
activ
hbov
appli
date
nichol
et
al
rapid
hbov
test
method
capabl
identifi
clinic
relev
case
could
reduc
unjustifi
gener
ineffect
use
antibiot
patient
pathogenet
role
hbov
turn
signific
need
vaccin
develop
probabl
investig
schildgen
et
al
coronavirus
consist
import
group
rna
virus
classifi
famili
coronavirida
order
niroviridal
two
human
coronavirus
character
group
coronaviru
group
ii
coronaviru
sinc
three
new
hcov
identifi
group
coronaviru
van
der
hoek
et
al
esper
et
al
group
ii
coronaviru
woo
et
al
sar
coronaviru
marra
et
al
found
worldwid
seem
preval
winter
infect
occur
age
common
children
year
age
health
protect
agenc
virus
detect
patient
acut
respiratori
tract
infect
wherea
coinfect
respiratori
virus
common
van
der
hoek
et
al
hcov
also
detect
solid
organ
transplant
recipi
patient
underli
malign
individu
infect
hiv
kumar
et
al
among
patient
admit
hospit
acut
respiratori
symptom
hcov
detect
hcov
infect
found
immunocompromis
patient
immunocompet
patient
gerna
et
al
associ
respiratori
tract
diseas
children
adult
chiu
et
al
clear
link
respiratori
diseas
establish
pyrc
et
al
may
common
caus
croup
associ
coronaviru
kawasaki
diseas
esper
et
al
put
question
later
studi
rowley
shulman
respiratori
symptom
accompani
infect
usual
rhinorrhea
fever
cough
wheez
diseas
manifest
includ
bronchiol
pneumonia
lau
et
al
sloot
et
al
infect
may
limit
respiratori
tract
viru
also
detect
fecal
sampl
common
cold
virus
result
sever
clinic
manifest
young
children
elderli
person
immunocompromis
patient
pyrc
et
al
amplif
method
wide
use
respiratori
coronaviru
diagnosi
avail
serolog
test
efficaci
cell
cultur
mani
coronavirus
limit
pancoronaviru
primer
set
claim
detect
coronavirus
describ
et
al
confirm
consensu
primer
perfectli
match
van
der
hoek
et
al
howev
genet
variabl
among
mani
coronaviru
infect
detect
avail
pancoronaviru
method
use
gerna
et
al
bp
fragment
use
specif
target
gene
van
der
hoek
et
al
wherea
primer
mainli
defin
replicas
gene
woo
et
al
emerg
sarscov
intensifi
antivir
research
cov
nichol
et
al
antivir
compound
target
human
coronavirus
exampl
broadspectrum
inhibitor
pro
enzym
promis
sever
compound
effici
inhibit
distinct
step
viral
replic
cycl
describ
pyrk
et
al
nevertheless
need
develop
antivir
strategi
specif
well
may
limit
due
low
incid
seriou
respiratori
tract
diseas
kahn
human
human
member
genu
roseoloviru
subfamili
betaherpesvirina
berneman
et
al
first
isol
peripher
blood
mononuclear
cell
patient
lymphoprolif
disord
salahuddin
et
al
two
subtyp
type
type
b
braun
et
al
origin
isol
lymphocyt
obtain
healthi
adult
frenkel
et
al
ubiquit
remain
latent
cell
primari
infect
reactiv
immunocompromis
host
khanani
et
al
phenomenon
chromosom
integr
ci
latent
state
viru
chromosom
kept
mind
altern
caus
detect
suspect
case
ljungman
et
al
epidemiolog
infect
popul
age
respect
thought
transmit
saliva
salivari
shed
viru
document
adult
dewhurst
reactiv
occur
transplant
patient
earli
transplant
detect
blood
median
day
transplant
usual
cmv
detect
type
b
significantli
common
type
incid
reactiv
higher
allogen
cord
blood
stem
cell
transplant
allogen
bone
marrow
transplant
andor
peripher
blood
stem
cell
transplant
sashihara
et
al
tomonari
et
al
younger
age
underli
malign
beyond
earli
phase
ie
diagnos
hematolog
malign
first
remiss
cml
chronic
phase
allogen
transplant
unrel
mismatchedrel
gender
mismatch
donor
use
antitcel
antibodi
steroid
identifi
predictor
reactiv
zerr
posit
associ
detect
relat
among
cmv
ebv
shown
studi
pediatr
hematopoiet
cell
transplant
recipi
chan
et
al
hubacek
et
al
high
incid
viremia
detect
pediatr
stem
cell
recipi
chan
et
al
savolainen
et
al
studi
adult
pediatr
patient
viremia
posttranspl
rang
hubacek
et
al
nevertheless
anoth
studi
pediatr
stem
cell
recipi
incid
found
khanani
et
al
primari
infect
commonli
manifest
undifferenti
highli
febril
ill
approxim
children
exhibit
classic
clinic
manifest
exanthem
subitum
complic
febril
seizur
dewhurst
immunocompet
adult
primari
infect
produc
mononucleosislik
ill
rare
sever
diseas
includ
enceph
stoeckl
hematopoiet
transplant
patient
reactiv
associ
skin
rash
fever
myelosuppress
pneumon
may
exarceb
gvhd
central
nervou
system
disord
enceph
also
link
although
caus
relationship
incid
yet
fulli
clarifi
yaman
et
al
enceph
posthematopoiet
cell
transplant
rel
rare
approxim
case
publish
ljungman
et
al
primari
infect
also
caus
exanthem
subitum
although
less
frequent
like
associ
seizur
furthermor
detect
case
inflammatori
skin
disord
psoriasi
although
data
detect
pityriasi
rosea
controversi
kempf
recent
studi
reveal
causal
role
broccolo
et
al
canpolat
kirac
et
al
allogen
hematopoiet
cell
transplant
report
caus
sever
central
nervou
system
diseas
castagnola
et
al
addit
associ
sever
gvhd
sepsi
secondari
sever
immunosuppress
transplant
match
unrel
donor
khanani
et
al
role
poorli
defin
hematopoiet
cell
transplant
recipi
ljungman
et
al
studi
hematopoiet
cell
transplant
recipi
diagnosi
reli
detect
sinc
serolog
method
gener
consid
unreli
sever
immunocompromis
patient
expert
agre
isol
blood
detect
viral
dna
serum
plasma
indic
activ
viral
infect
zerr
far
concern
pcr
antigen
detect
consid
reliabl
diagnost
tool
savolainen
et
al
amplif
specif
dna
mainli
perform
use
primer
u
gene
savolainen
et
al
wherea
primer
mainli
locat
region
chan
et
al
limit
data
publish
regard
efficaci
antivir
therapi
long
et
al
studi
effect
ganciclovir
grow
evid
ganciclovir
inhibit
replic
salivari
gland
vitro
activ
acyclovir
ganciclovir
cidofovir
foscarnet
compar
cidofovir
appear
potent
also
select
least
subtyp
cord
blood
lymphocyt
tcell
line
highest
select
score
four
compound
achiev
foscarnet
de
clercq
naesen
littl
known
regard
treatment
diseas
although
vitro
studi
indic
much
less
suscept
ganciclovir
foscarnet
suggest
potenti
use
agent
dewhurst
first
human
polyomavirus
bk
viru
bkv
jc
viru
jcv
coincid
isol
two
independ
group
bkv
urin
renal
transplant
patient
suffer
ureter
stenosi
gardner
et
al
jcv
brain
tissu
patient
hodgkin
lymphoma
develop
progress
multifoc
leukoencephalopathi
padgett
et
al
recent
two
new
member
human
polyomaviru
famili
ki
viru
kiv
wu
viru
wuv
identifi
respiratori
specimen
mainli
children
year
age
respiratori
tract
infect
alland
et
al
gaynor
et
al
seropreval
bkv
rang
gener
popul
primari
infect
usual
occur
childhood
earlier
age
jcv
rout
transmiss
bkv
jcv
remain
unclear
despit
evid
suggest
respiratori
transmiss
jiang
et
al
asymptomat
reactiv
infect
urinari
shed
may
occur
immunocompet
individu
immunosuppress
bkv
infect
may
reactiv
asymptomat
bk
viruria
occur
immunocompet
individu
immunocompromis
patient
hirsch
stem
cell
transplant
recipi
recent
studi
bk
viruria
relat
pretranspl
detect
antibkv
igg
antibodi
relationship
serolog
evid
bkv
bk
viruria
hemorrhag
cystiti
remain
unclear
wong
et
al
primari
jcv
infect
childhood
occur
popul
result
lifelong
viral
latenc
kidney
bcell
lymphocyt
goldberg
et
al
immunocompromis
host
jcv
associ
progress
multifoc
leukoencephalopathi
caus
reactiv
latent
infect
rather
de
novo
exposur
kharfandabaja
et
al
report
suggest
kiv
wuv
worldwid
endem
infect
common
earli
winter
month
gather
evid
primari
infect
kiv
wuv
occur
childhood
jiang
et
al
kiv
wuv
infect
similar
frequenc
rang
norja
et
al
immunosuppress
individu
frequenc
higher
retrospect
studi
nasopharyng
aspir
bronchoalveolar
lavag
sampl
immunocompromis
patient
suspect
upper
lower
respiratori
tract
infect
preval
kiv
wuv
respect
furthermor
kiv
infect
among
hematopoiet
graft
recipi
occur
suggest
profound
tcell
defici
could
play
role
kiv
replic
high
preval
kiv
among
immunocompromis
patient
indic
popul
may
suscept
kiv
jcv
bkv
respiratori
coinfect
common
mourez
et
al
frequent
report
manifest
bkv
infect
follow
hematopoiet
cell
transplant
hemorrhag
cystiti
fioriti
et
al
character
dysuria
vari
degre
hematuria
affect
hematopoiet
cell
transplant
patient
dropul
jone
bkv
nephropathi
allogen
hematopoiet
cell
transplant
report
adult
pediatr
set
case
even
without
evid
hemorrhag
cystiti
tcell
deplet
exor
vivo
graft
gvhd
associ
profound
immunosuppress
exarceb
treatment
potenti
risk
factor
must
valid
verghes
et
al
lekaki
et
al
jcv
caus
progress
multifoc
leukoencephalopathi
infect
oligodendrocyt
astrocyt
duboi
et
al
literatur
six
report
case
progress
multifoc
leukoencephalopathi
allogen
transplant
eight
autolog
transplant
diseas
may
present
varieti
neurolog
manifest
hemiparesi
visual
impair
aphasia
headach
vertigo
seizur
among
other
outcom
fatal
case
kharfandabaja
et
al
despit
clear
presenc
specimen
patient
respiratori
ill
pathogen
role
kiv
wuv
remain
unclear
studi
includ
defin
nonrespiratori
diseas
control
group
kiv
wuv
detect
similar
frequenc
asymptomat
patient
kiv
wuv
detect
asymptomat
patient
well
patient
upper
lower
respiratori
tract
infect
immunocompromis
patient
spectrum
diseas
kivand
wuvinfect
patient
rang
common
cold
acut
respiratori
distress
mourez
et
al
evid
viral
multipl
lytic
activ
infect
detect
viral
cultur
electron
microscopi
immunohistochemistri
pcr
method
express
mrna
viral
dna
nonquiesc
site
plasma
cytolog
histolog
examin
whether
infecti
wuv
kiv
particl
isol
grown
laboratori
remain
unclear
jiang
et
al
primer
target
region
use
detect
kiv
wuv
respect
alland
et
al
gaynor
et
al
although
two
virus
differ
substanti
aminoacid
sequenc
protein
close
phylogenet
relat
bkv
jcv
zur
hausen
bkv
plasma
level
greater
copiesml
highli
associ
postengraft
bkvassoci
hemorrhag
cystiti
among
patient
undergon
hematopoiet
cell
transplant
screen
hematopoiet
cell
transplant
patient
bkv
would
benefici
assess
need
earli
support
intervent
overt
clinic
diseas
evid
definit
diagnosi
bkv
nephropathi
requir
biopsi
verghes
et
al
although
pcr
csf
emerg
promis
tool
detect
jcv
neg
result
rule
progress
multifoc
leukoencephalopathi
therefor
brain
biopsi
remain
gold
standard
diagnost
tool
signific
jcv
viremia
potenti
role
progress
multifoc
leukoencephalopathi
screen
tool
hematopoiet
transplant
recipi
remain
assess
kharfandabaja
et
al
time
effect
specif
antivir
treatment
bkv
exist
best
choic
therapeut
intervent
current
avail
fluoroquinolon
leflunomid
cidofovir
ivig
combin
therapi
optim
time
treatment
initi
current
unknown
efficaci
treatment
option
remain
explor
jiang
et
al
lekaki
et
al
establish
treatment
progress
multifoc
leukoencephalopathi
autolog
allogen
transplant
treatment
option
includ
cytarabin
cidofovir
combin
therapi
withdraw
immunosuppress
kharfandabaja
et
al
chlorpromazin
newgener
atyp
antipsychot
ziprasidon
risperidon
olanzapin
may
use
therapi
progress
multifoc
leukoencephalopathi
pho
et
al
atwood
altschul
kast
appar
spectrum
viral
infect
hematopoiet
transplant
recipi
expand
welldesign
prospect
studi
focus
diagnost
tool
manag
need
defin
diseas
burden
newli
discov
virus
bocaviru
novel
coronavirus
polyomavirus
elimin
risk
morbid
mortal
emerg
viral
infect
hematopoiet
graft
recipi
furthermor
effect
vaccin
specif
antivir
compound
new
pathogen
warrant
